A Case for Weekly Basal Insulin

In the final video, PA Orr presents the case of a 59-year-old man with type 2 diabetes who has trouble keeping up with daily insulin glargine because of frequent work travel. She describes his clinical picture, his questions about efficacy and hypoglycemia, and the questions she asked him about his eating, travel, and sleep patterns.

She then explains how they switched him to once-weekly insulin icodec, including the dose calculation and the first-week adjustment. PA Orr describes follow-up plans for this patient and shares her guidance for missed doses when traveling.

Key Takeaways:

  1. Switching from daily to weekly insulin dosing starts with a straightforward conversion and titrating if needed.
  2. Weekly dosing can alleviate some of the challenges with basal insulin.
  3. Blood glucose monitoring remains critical regardless of dosing schedule.

Previous Video Next Series

Speaker

Click on the photo below to learn more about the speaker.

References and Additional Resources:

AWIQLI. Prescribing Information. Novo Nordisk, Inc.; 2026. https://www.novo-pi.com/awiqli.pdf

Shubrook JH. What primary care clinicians need to know about once-weekly insulins. Fed Pract. 2024;41(suppl 6):S47-S52. https://pmc.ncbi.nlm.nih.gov/articles/PMC11745467/

Supported by